Working… Menu

Study of Phenobarbital Inhibition of Catamenial Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00530413
Recruitment Status : Withdrawn (IRB needs updated)
First Posted : September 17, 2007
Last Update Posted : December 10, 2014
Information provided by (Responsible Party):
University of Toledo Health Science Campus

Brief Summary:

The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy.

We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Phenobarbital Other: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of Phenobarbital Inhibition of Catamenial Epilepsy
Study Start Date : March 2007
Estimated Primary Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy

Arm Intervention/treatment
Experimental: 1
Phenobarbital - dose based by weight range
Drug: Phenobarbital
Phenobarbital will be given based on weight range

Placebo Comparator: 2
Placebo group
Other: Placebo
Placebo group

Primary Outcome Measures :
  1. Patient Health Questionnaire (PHQ-9) [ Time Frame: Screening, 3 month and final visit ]
  2. Depression Epworth Sleepiness Scale (ESS) [ Time Frame: Screening, 3 month and final visit ]
  3. Quality of Life in Epilepsy (QOLIE-10) [ Time Frame: Screening, 3 month and Final Visit ]
  4. Addenbrooke's Cognitive Examination (ACE) [ Time Frame: Screening, 3 month and Final Visit ]

Secondary Outcome Measures :
  1. Determine tolerance of medication using the depression, cognitive and sleepiness screening tools listed above [ Time Frame: Screening, 3 months, final visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult female patients seeking medical attention for seizures
  • Regular menstrual cycles
  • At least 2 seizures per month
  • Must be on at least one form of birth control other than abstinence
  • Must be on a stable anticonvulsant regimen of at least one and not exceeding three anticonvulsants, and not be using any perimenstrual seizure medications of hormone preparations
  • If taking benzodiazepines for therapeutic purposes, must be on a stable regular dose
  • Must be willing to take at least 400mcg of folic acid a day while in the study
  • Must be able to detect, count or record seizures

Exclusion Criteria:

  • Can not be pregnant or trying to become pregnant
  • Can not have used hormonal birth control methods for at least 3 months prior to enrollment
  • Can not have an allergy to Phenobarbital
  • Can not have a history of non-epileptic seizures
  • Can not have a know liver dysfunction or history of chronic hepatitis
  • Can not have a history of neurological disorder or history of status epilepticus in the preceding year
  • Can not ahve a physical or psychiatric condition which in the PIs opinion could compromise her ability to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00530413

Layout table for location information
United States, Ohio
University of Toledo, Health Science Campus
Toledo, Ohio, United States, 43606
Sponsors and Collaborators
University of Toledo Health Science Campus
Layout table for investigator information
Principal Investigator: Lazar J Greenfield, Jr, MD, PhD University of Toledo Health Science Campus
Layout table for additonal information
Responsible Party: University of Toledo Health Science Campus Identifier: NCT00530413    
Other Study ID Numbers: xUTHSC-07
First Posted: September 17, 2007    Key Record Dates
Last Update Posted: December 10, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
GABA Agents
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP3A Inducers